216 related articles for article (PubMed ID: 24362527)
1. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention.
Stampolidis P; Ullrich A; Iacobelli S
Oncogene; 2015 Jan; 34(1):39-52. PubMed ID: 24362527
[TBL] [Abstract][Full Text] [Related]
2. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.
Piccolo E; Tinari N; Semeraro D; Traini S; Fichera I; Cumashi A; La Sorda R; Spinella F; Bagnato A; Lattanzio R; D'Egidio M; Di Risio A; Stampolidis P; Piantelli M; Natoli C; Ullrich A; Iacobelli S
J Mol Med (Berl); 2013 Jan; 91(1):83-94. PubMed ID: 22864925
[TBL] [Abstract][Full Text] [Related]
3. Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line.
Woo JK; Jang JE; Kang JH; Seong JK; Yoon YS; Kim HC; Lee SJ; Oh SH
Mol Cancer Ther; 2017 Jul; 16(7):1355-1365. PubMed ID: 28336809
[TBL] [Abstract][Full Text] [Related]
4. Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).
Zambelli D; Zuntini M; Nardi F; Manara MC; Serra M; Landuzzi L; Lollini PL; Ferrari S; Alberghini M; Llombart-Bosch A; Piccolo E; Iacobelli S; Picci P; Scotlandi K
Int J Cancer; 2010 Jan; 126(1):41-52. PubMed ID: 19544526
[TBL] [Abstract][Full Text] [Related]
5. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.
Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A
J Biol Chem; 2014 Nov; 289(48):33481-91. PubMed ID: 25320078
[TBL] [Abstract][Full Text] [Related]
6. Increased LGALS3BP promotes proliferation and migration of oral squamous cell carcinoma via PI3K/AKT pathway.
Zhang X; Ding H; Lu Z; Ding L; Song Y; Jing Y; Hu Q; Dong Y; Ni Y
Cell Signal; 2019 Nov; 63():109359. PubMed ID: 31302247
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.
Traini S; Piccolo E; Tinari N; Rossi C; La Sorda R; Spinella F; Bagnato A; Lattanzio R; D'Egidio M; Di Risio A; Tomao F; Grassadonia A; Piantelli M; Natoli C; Iacobelli S
Mol Cancer Ther; 2014 Apr; 13(4):916-25. PubMed ID: 24552775
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of LGALS3BP in human colorectal carcinoma.
Piccolo E; Tinari N; D'Addario D; Rossi C; Iacobelli V; La Sorda R; Lattanzio R; D'Egidio M; Di Risio A; Piantelli M; Natali PG; Iacobelli S
J Transl Med; 2015 Jul; 13():248. PubMed ID: 26219351
[TBL] [Abstract][Full Text] [Related]
9. Lectin galactoside-binding soluble 3 binding protein mediates methotrexate resistance in choriocarcinoma cell lines.
Chen X; Xue Y; Wang L; Weng Y; Li S; Lü W; Xie X; Cheng X
Bioengineered; 2022 Feb; 13(2):2076-2086. PubMed ID: 35038949
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
11. Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target.
Capone E; Iacobelli S; Sala G
J Transl Med; 2021 Sep; 19(1):405. PubMed ID: 34565385
[TBL] [Abstract][Full Text] [Related]
12. LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells.
Fogeron ML; Müller H; Schade S; Dreher F; Lehmann V; Kühnel A; Scholz AK; Kashofer K; Zerck A; Fauler B; Lurz R; Herwig R; Zatloukal K; Lehrach H; Gobom J; Nordhoff E; Lange BM
Nat Commun; 2013; 4():1531. PubMed ID: 23443559
[TBL] [Abstract][Full Text] [Related]
13. Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression.
Song Y; Wang M; Tong H; Tan Y; Hu X; Wang K; Wan X
Oncogene; 2021 Jan; 40(3):633-646. PubMed ID: 33208911
[TBL] [Abstract][Full Text] [Related]
14. Effect of intraoral mechanical stress application on the expression of a force-responsive prognostic marker associated with system disease progression.
Zhang Y; Kou X; Jiang N; Liu Y; Tay FR; Zhou Y
J Dent; 2017 Feb; 57():57-65. PubMed ID: 27979689
[TBL] [Abstract][Full Text] [Related]
15. LGALS3BP is a novel and potential biomarker in clear cell renal cell carcinoma.
Li L; Qin S; Tan H; Zhou J
Aging (Albany NY); 2024 Feb; 16(4):4033-4051. PubMed ID: 38393692
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation.
White MJ; Roife D; Gomer RH
J Immunol; 2015 Aug; 195(4):1858-67. PubMed ID: 26136428
[TBL] [Abstract][Full Text] [Related]
17. Platelet LGALS3BP as a Mediator of Myeloid Inflammation in Systemic Lupus Erythematosus.
El Bannoudi H; Cornwell M; Luttrell-Williams E; Engel A; Rolling C; Barrett TJ; Izmirly P; Belmont HM; Ruggles K; Clancy R; Buyon J; Berger JS
Arthritis Rheumatol; 2023 May; 75(5):711-722. PubMed ID: 36245285
[TBL] [Abstract][Full Text] [Related]
18. MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain.
Wang H; Jiang X; Cheng Y; Ren H; Hu Y; Zhang Y; Su H; Zou Z; Wang Q; Liu Z; Zhang J; Qiu X
Cancer Sci; 2021 Jun; 112(6):2210-2222. PubMed ID: 33754417
[TBL] [Abstract][Full Text] [Related]
19. The GALNT6‑LGALS3BP axis promotes breast cancer cell growth.
Kimura R; Yoshimaru T; Matsushita Y; Matsuo T; Ono M; Park JH; Sasa M; Miyoshi Y; Nakamura Y; Katagiri T
Int J Oncol; 2020 Feb; 56(2):581-595. PubMed ID: 31894262
[TBL] [Abstract][Full Text] [Related]
20. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M
Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
